3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study.

Area of Science:

• Cardiology
• Interventional Cardiology
• Biomedical Engineering

Background:

• Limited data exists on transcatheter aortic valve replacement (TAVR) outcomes beyond two years in low-surgical risk patients with bicuspid aortic stenosis.
• Bicuspid aortic valve anatomy presents unique challenges for TAVR procedures.

Purpose of the Study:

• To evaluate the 3-year clinical and echocardiographic outcomes of TAVR using the Evolut self-expanding bioprosthesis in patients with low surgical risk and bicuspid aortic stenosis.
• To assess the safety and efficacy of TAVR in this specific patient population.

Main Methods:

• Prospective, multicenter, single-arm study (Evolut Low Risk Bicuspid Study) involving 150 low-risk patients with severe aortic stenosis and bicuspid aortic valve anatomy.
• Patients received a self-expanding, supra-annular Evolut R or PRO bioprosthesis.
• Clinical events and echocardiographic data were independently adjudicated and assessed.

Main Results:

• The 3-year Kaplan-Meier rate for all-cause mortality or disabling stroke was 4.1%.
• No moderate or severe paravalvular aortic regurgitation was observed at 2 or 3 years post-TAVR.
• The incidence of new permanent pacemaker implantation was 19.4% at 3 years.

Conclusions:

• The Evolut Low Risk Bicuspid Study demonstrates favorable 3-year clinical outcomes for TAVR in low-risk patients with bicuspid aortic stenosis.
• The findings support the use of this TAVR device in this population, showing low mortality/stroke rates and good hemodynamic performance.